Project Grant R21AG089843
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$446K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45221, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $660,875 will support research to investigate the protective effect of African-derived APOE alleles on Alzheimer's disease (AD) risk through pleiotropy. The University of Washington will conduct this study, which aims to determine which variants on African-derived and European-derived APOE haplotypes may explain the association between African-derived APOE alleles and reduced AD risk, and...
This Project Grant award, funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), will investigate the mechanisms by which a genetic variant in the APOE gene, APOE R145C, contributes to the elevated Alzheimer's disease (AD) risk observed in African American populations. The $235,500 award will utilize human induced pluripotent stem cells (hiPSCs) to model the effects of the APOE R145C variant on AD-related cellular phenotypes, including amyloid-beta processing...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,550,462 to Georgetown University to conduct a 5-year study examining the impact of Alzheimer's disease risk genes, particularly APOE E4, on brain function in older Black/African Americans living with HIV. The study will enroll 120 HIV-positive participants and 80 demographically matched controls, and utilize a combination of neuropsychological tests, neuroimaging, biomarker...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $804,450 aims to investigate the mechanisms by which the major Alzheimer's disease genetic risk factor APOE4 interacts with sex and aging to contribute to neuronal dysfunction and cognitive decline. The key objectives are to: 1) Validate the protective effects of deleting the NELL2 protein in hippocampal excitatory neurons of APOE4 knock-in mice, and 2) Examine the transcriptomic and...
This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) totaling $424,184 aims to understand racial and ethnic disparities in access to Alzheimer's Special Care Units (SCUs) in nursing homes and how this access affects health outcomes. The project will: 1) Examine disparities in SCU access among Black and Hispanic residents with Alzheimer's disease and related dementias (ADRD); 2) Assess how SCU access contributes to disparities in ADRD...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $235,795 Project Grant (CFDA 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of California, Irvine to conduct research on developing a Black aging cohort in Southern California. The project aims to identify structural and social determinants of health (SDOH) that impact Black communities' willingness to participate in Alzheimer's disease and related dementias...
The U.S. National Institute on Aging (NIA) awarded a $1,649,586 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the Sanford Burnham Prebys Medical Discovery Institute (SBP) to conduct research on developing small molecule "correctors" that can functionally convert the Alzheimer's disease-associated APOE4 protein to be more like the protective APOE3 variant. The project aims to optimize these APOE4 correctors as potential therapeutic interventions for...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $769,710 will support research to examine the impact of upward socioeconomic mobility during adolescence on cognitive health and Alzheimer's disease (AD) risk factors in young adulthood. The project will leverage an existing cohort from the Reducing Inequities through Social and Educational Change Follow-up (RISE-UP) study to compare young adults who had the opportunity for greater...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Roskamp Institute, Inc. in Sarasota, Florida provides $449,460 in funding to support research investigating the role of cerebrovascular dysfunction and bioenergetic deficits in the increased Alzheimer's disease risk associated with the APOE4 genetic variant. The research aims to determine how APOE4 disrupts L-carnitine-mediated bioenergetic pathways in brain endothelial and mural cells, and...